California-Arizona Clinical Trials Network Node

描述(由申请人提供)：加州大学旧金山分校(UCSF)提议达成一项合作协议，在国家药物滥用治疗临床试验网络(CTN)中领导一个节点。研究节点的总体目标是参与和进行药物滥用和成瘾干预措施的高质量多点临床试验，并指导制定、传播和采用该领域的有效干预措施。我们的研究节点将由加州大学旧金山分校的区域研究和培训中心(PRTC)组成，该中心与亚利桑那大学的研究人员以及加利福尼亚州和亚利桑那州的社区治疗计划(CTP)建立了合作关系。我们的加州-亚利桑那州研究节点将促进研究，以提高对鸦片类药物、可卡因和甲基苯丙胺、尼古丁和其他滥用药物成瘾的治疗效果。研究和治疗之间的差距是药物滥用中最关键的悬而未决的问题之一。该节点将促进科学家和实践者之间的合作，以鼓励新的研究，提高社区环境中药物滥用治疗的有效性。拟议的研究节点的目标是：(1)参与药物滥用和成瘾的行为、药理和联合疗法的临床试验；(2)与国家CTN领导合作开发和实施研究研究，特别关注艾滋病毒、吸烟和丙型肝炎等共生问题的患者；以及发展和维护(3)行政基础设施(4)研究基础设施和(5)实现这些目标的临床基础设施。NIDA CTN可以在缩小药物滥用研究和治疗之间的差距方面发挥重要作用。这一研究节点有可能在未来十年加快临床试验和转化性研究的进展。

DESCRIPTION (provided by applicant): The University of California, San Francisco (UCSF) proposes a cooperative agreement to lead a node in the National Institute on Drug Abuse Treatment Clinical Trials Network (CTN). The overall goal of the Research Node is to participate in and conduct high-quality multi-site clinical trials of interventions for drug abuse and addiction and to guide the development, dissemination, and adoption of effective interventions in the field. Our Research Node will consist of a Regional Research and Training Center (PRTC) at UCSF that is linked in partnership with researchers at the University of Arizona and with community-based treatment programs (CTPs) in California and Arizona. Our California-Arizona Research Node will stimulate research to improve the effectiveness of treatment of addiction to opiates, cocaine and methamphetamine, nicotine, and other abused drugs. The gap between research and treatment is one of the most critical unresolved issues in drug abuse. The Node will foster collaboration among scientists and practitioners to stimulate new research improving the effectiveness of drug abuse treatment in community settings. The aims for the proposed Research Node are: (1) to participate in clinical trials of behavioral, pharmacological, and combined therapies for drug abuse and addiction; (2) to work with the national CTN leadership in development and implementation of research studies with special attention to patients with such co-occurring problems such as HIV, smoking, and hepatitis C; and to develop and maintain (3) an administrative infrastructure (4) a research infrastructure, and (5) a clinical infrastructure to accomplish these aims. The NIDA CTN can have a significant role in closing the gap between research and treatment in drug abuse. This Research Node has the potential to accelerate the advance of clinical trials and translational research over the coming decade.